Characterization of T cell clones derived from lymph nodes and lungs of Pseudomonas aeruginosa-susceptible and resistant mice following immunization with heat-killed bacteria.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Characterization of T cell clones derived from lymph nodes and lungs of Pseudomonas aeruginosa-susceptible and resistant mice following immunization with heat-killed bacteria.

Clin Exp Immunol. 2000 Aug;121(2):275-82. Unique Identifier : AIDSLINE MED/20389931
Kondratieva TK; Kobets NV; Khaidukov SV; Yeremeev VV; Lyadova IV; Apt AS; Tam MF; Stevenson MM; Experimental Immunogenetics Laboratory, Central Institute for; Tuberculous and Laboratory for Immunochemistry, Shemyakin and; Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia.

Abstract: Pseudomonas aeruginosa-resistant BALB/c and susceptible C57Bl/6 (B6) mice were immunized with heat-killed Pseudomonas either in the foot pad or via the trachea, and panels of Pseudomonas-specific T cell clones were developed from lymph nodes and lungs. All clones from either strain, whether of lymph node or lung origin, were CD3+CD4+CD8-TCRalphabeta+. The efficacy of cloning from lymph node cells was comparable between BALB/c and B6 mice. All lymph node BALB/c clones proliferated in response to Pseudomonas antigen in a dose-dependent manner, and this response was MHC class II-restricted. Vigorous proliferation by a considerable proportion of B6 T cell clones occurred in the absence of specific antigen. Lymph node clones from either strain could be categorized as either Th1 or Th0 on the basis of interferon-gamma (IFN-gamma)/IL-4 production. In either mouse strain the efficacy of cloning from lung tissue was substantially lower than from lymph nodes, but the efficacy of cloning from BALB/c compared with B6 lungs was higher. Four lung T cell clones from BALB/c and two from B6 mice were expanded for further analyses, and an interstrain difference was observed in cytokine production. Both B6 lung T cell clones were Th1-like and produced IFN-gamma but not IL-4 and IL-10, whereas four BALB/c lung T cell clones were Th2-like and produced IL-4 and IL-10 but not IFN-gamma. These observations suggest that differences in the CD4+ Th response in the lung may contribute to differences among inbred mouse strains in the level of resistance to bronchopulmonary Pseudomonas infection.

Keywords: JOURNAL ARTICLE Animal Antigens, Bacterial/IMMUNOLOGY Bacterial Vaccines/*IMMUNOLOGY Cells, Cultured Clone Cells/IMMUNOLOGY Comparative Study Genetic Predisposition to Disease Histocompatibility Antigens Class II/IMMUNOLOGY Immunity, Natural Immunophenotyping Interferon Type II/SECRETION Interleukin-10/SECRETION Interleukin-4/SECRETION Lung/*PATHOLOGY Lymph Nodes/*PATHOLOGY Lymphocyte Transformation Mice Mice, Inbred BALB C Mice, Inbred C57BL Pseudomonas aeruginosa/*IMMUNOLOGY Pseudomonas Infections/*PREVENTION & CONTROL Support, Non-U.S. Gov't T-Lymphocyte Subsets/*IMMUNOLOGY/SECRETION Th1 Cells/IMMUNOLOGY/SECRETION Th2 Cells/IMMUNOLOGY/SECRETION *Vaccination Vaccines, Inactivated/IMMUNOLOGY

001130
A00B1163

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .